- Home
- SXC vs REPL Comparison
SXC vs REPL Comparison
Compare SXC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- REPL
- Stock Information
- Founded
- SXC 1960
- REPL 2015
- Country
- SXC United States
- REPL United States
- Employees
- SXC N/A
- REPL N/A
- Industry
- SXC Steel/Iron Ore
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- REPL Health Care
- Exchange
- SXC Nasdaq
- REPL Nasdaq
- Market Cap
- SXC 802.2M
- REPL 1.1B
- IPO Year
- SXC N/A
- REPL 2018
- Fundamental
- Price
- SXC $9.20
- REPL $13.98
- Analyst Decision
- SXC Strong Buy
- REPL Strong Buy
- Analyst Count
- SXC 1
- REPL 6
- Target Price
- SXC $13.00
- REPL $19.83
- AVG Volume (30 Days)
- SXC 1.1M
- REPL 624.5K
- Earning Date
- SXC 01-30-2025
- REPL 02-12-2025
- Dividend Yield
- SXC 5.22%
- REPL N/A
- EPS Growth
- SXC 64.98
- REPL N/A
- EPS
- SXC 1.12
- REPL N/A
- Revenue
- SXC $1,935,400,000.00
- REPL N/A
- Revenue This Year
- SXC N/A
- REPL N/A
- Revenue Next Year
- SXC $3.70
- REPL $1,065.54
- P/E Ratio
- SXC $8.21
- REPL N/A
- Revenue Growth
- SXC N/A
- REPL N/A
- 52 Week Low
- SXC $7.47
- REPL $4.92
- 52 Week High
- SXC $12.82
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- SXC 34.90
- REPL 55.54
- Support Level
- SXC $9.74
- REPL $13.40
- Resistance Level
- SXC $10.08
- REPL $14.59
- Average True Range (ATR)
- SXC 0.30
- REPL 0.84
- MACD
- SXC -0.00
- REPL -0.02
- Stochastic Oscillator
- SXC 4.84
- REPL 66.52
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.